Vutrisiran Sodium

Summary

Vutrisiran Sodium (CHEMBL5095303) is an approved oligonucleotide; indicated across 2 conditions including familial amyloid neuropathy and polyneuropathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligonucleotide
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095303
Name	Vutrisiran Sodium
Type	Oligonucleotide
Max phase	4

Also known as: ALN-65492 SODIUM, ALN-TTRSC02, Amvuttra, Votrisiran sodium, Vutrisiran sodium, VUTRISIRAN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
familial amyloid neuropathy	4	MONDO:0007100	EFO:0004129
polyneuropathy	4	MONDO:0001824	EFO:0009562

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02797847	PHASE1	COMPLETED	A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).